thisdrug what a medicine's name tells you

WHO naming stem · suffix · 24 listed names

-sartan

This page was written with AI.

angiotensin II receptor antagonists, antihypertensive (non-peptidic)

WHO's definition, quoted as written in the 2024 stem book

10 of 24 names appear in these lists: 9 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 8 have national brands in at least one EU/EEA country.

Names only. This page is about -sartan as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -sartan. So the letters sartan sit at the end of the name (…sartan).

All 24 names WHO lists under -sartan

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 10 of 24 names appear in these lists: 9 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 8 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. abitesartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. azilsartan
    in combination: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE with chlorthalidone; EDARBYCLOR with chlorthalidone
    EU (central) brands: Edarbi, Ipreziv (withdrawn)
  3. azilsartan medoxomil
    US brands: none found
    EU (central) brands: Edarbi, Ipreziv (withdrawn)
  4. azilsartan mepixetil
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. azilsartan mopivabil
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. candesartan
    US brands: ATACAND
    in combination: ATACAND HCT with hydrochlorothiazide
    EU (central) brands: none found
  7. elisartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  8. embusartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. eprosartan
    US brands: TEVETEN (discontinued in FDA listings)
    in combination: TEVETEN HCT (discontinued in FDA listings) with hydrochlorothiazide
    EU (central) brands: none found
  10. fimasartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  11. forasartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. irbesartan
    US brands: AVAPRO
    in combination: AVALIDE with hydrochlorothiazide
    EU (central) brands: Aprovel, Ifirmasta, Irbesartan Teva, Irbesartan Zentiva, Karvea, Irbesartan BMS (withdrawn), Sabervel (expired)
    in combination: CoAprovel with hydrochlorothiazide; Ifirmacombi with hydrochlorothiazide; Irbesartan Hydrochlorothiazide Zentiva with hydrochlorothiazide; Irbesartan/Hydrochlorothiazide Teva with hydrochlorothiazide; Karvezide with hydrochlorothiazide; Irbesartan Hydrochlorothiazide BMS (withdrawn) with hydrochlorothiazide
  13. losartan
    US brands: ARBLI, COZAAR
    in combination: HYZAAR with hydrochlorothiazide
    EU (central) brands: none found
  14. milfasartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. olmesartan
    US brands: BENICAR
    in combination: AZOR with amlodipine; BENICAR HCT with hydrochlorothiazide; TRIBENZOR with amlodipine + hydrochlorothiazide
    EU (central) brands: none found
  16. olmesartan medoxomil
    US brands: BENICAR
    in combination: AZOR with amlodipine; BENICAR HCT with hydrochlorothiazide; TRIBENZOR with amlodipine + hydrochlorothiazide
    EU (central) brands: none found
  17. pomisartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. pratosartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. ripisartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. saprisartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  21. tasosartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  22. telmisartan
    US brands: MICARDIS (discontinued in FDA listings)
    in combination: MICARDIS HCT with hydrochlorothiazide; TWYNSTA (discontinued in FDA listings) with amlodipine; WIDAPLIK (discontinued in FDA listings) with amlodipine + indapamide
    in combination: Actelsar HCT with hydrochlorothiazide; Kinzalkomb with hydrochlorothiazide; MicardisPlus with hydrochlorothiazide; PritorPlus with hydrochlorothiazide; Tolucombi with hydrochlorothiazide; Twynsta with amlodipine; Onduarp (withdrawn) with amlodipine
  23. valsartan
    US brands: DIOVAN, PREXXARTAN
    in combination: DIOVAN HCT with hydrochlorothiazide; ENTRESTO with sacubitril; ENTRESTO SPRINKLE with sacubitril; EXFORGE with amlodipine; EXFORGE HCT with amlodipine + hydrochlorothiazide; VYDUO with nebivolol; BYVALSON (discontinued in FDA listings) with nebivolol; VALTURNA (discontinued in FDA listings) with aliskiren
    EU (central) brands, in combination: Amlodipine / Valsartan Mylan with amlodipine; Copalia with amlodipine; Copalia HCT with amlodipine + hydrochlorothiazide; Dafiro with amlodipine; Dafiro HCT with amlodipine + hydrochlorothiazide; Entresto with sacubitril; Exforge with amlodipine; Exforge HCT with amlodipine + hydrochlorothiazide; Neparvis with sacubitril; Imprida (withdrawn) with amlodipine; Imprida HCT (lapsed) with amlodipine + hydrochlorothiazide
  24. zolasartan
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

losartan

Listed INNCarries the WHO stem -sartan

  • -sartanend of the nameWHO lists it hereWHO definition: angiotensin II receptor antagonists, antihypertensive (non-peptidic)

“losartan” is an INN that WHO lists under -sartan in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -sartan (Part II B) and the 24 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy